The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
A recent study supported by the National Institutes of Health (NIH) and published in Nature Neuroscience found that Alzheimer ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
A man from Kerala experienced severe body pain and fatigue upon seeking medical attention, he was diagnosed with rare ...
Enrollment in a 2025 Medicare plan opened for beneficiaries today. News outlets focus on an array of changes that could lead to "benefit disruption" that consumers should know about, in particular ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback